Our management team is made up of leaders in the field
Macrophage Therapeutics develops technologies to target and treat activated macrophages in the body using the proprietary technology of our parent company, Navidea Biopharmaceuticals Inc. (NYSE:NAVB).
Under our strong leadership, we are developing therapeutics to challenge some of the most feared diseases of our time, including cancer and HIV.
Michael M. Goldberg, MD
Chief Executive Officer
Michael M. Goldberg, M.D. has been Chief Executive Officer of Macrophage Therapeutics since its formation in January 2015.
He is also a member of the Navidea Biopharmaceuticals Board of Directors since his appointment in November 2013. Dr. Goldberg has been a Managing Partner of Montaur Capital Partners since January 2007. Prior to this, he served as the Chief Executive Officer of Emisphere Technologies, Inc., from August 1990 to January 16, 2007. Emisphere pioneered the development of oral delivery technology for macromolecules. Emisphere entered in numerous collaborations with large pharmaceutical companies, biotechnology companies and academic institutions. Dr. Goldberg holds a number of foundational patents in the field of drug delivery of macromolecules. Prior to Emisphere he was a founding member of the healthcare investment-banking group of The First Boston Corporation (now Credit Suisse), where he worked from 1985 –1990.
Dr. Goldberg is currently Chairman of the Board of Echo Therapeutics, Inc and a private company Urigen Pharmaceuticals, Inc. he has served on numerous other public and private company boards. Dr. Goldberg received a B.S. and M.D. degree from the combined six year biomedical program at Rensselaer Polytechnic Institute and the Albany Medical College of Union University in 1982, and an M.B.A. from the Columbia University Graduate School of Business in 1985 where he was a Samuel Bronfman fellow.